- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07480356
Wirksamkeit und Sicherheit von intravesikalem TARA-002 im Vergleich zur Wahl des Prüfarztes für intravesikale Chemotherapie bei Teilnehmern mit BCG-naivem hochgradigem nicht-muskelinvasivem Blasenkrebs (ADVANCED-3)
Eine Phase-3-Studie, randomisiert, zur Bewertung der Wirksamkeit und Sicherheit von intravesikalem TARA-002 im Vergleich zur Wahl des Prüfarztes für intravesikale Chemotherapie bei Teilnehmern mit BCG-naivem, hochgradigem nicht-muskelinvasivem Blasenkrebs
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.
The main questions it aims to answer are:
- Can the study drug help participants with this type of cancer?
- Is the study drug safe?
- What are the side effects of the study drug?
Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Chief R&D Officer
- Telefonnummer: 16468440337
- E-Mail: clinicaltrials@protaratx.com
Studienorte
-
-
-
Ivano-Frankivsk, Ukraine, 76018
- Rekrutierung
- Arenia - Ivano-Frankivsk
-
Kontakt:
- Use Central Contact
-
Kapitanivka, Ukraine, 08111
- Rekrutierung
- Arensia Kapitanivka - PPDS
-
Kontakt:
- Use Central Contact
-
-
-
-
Arizona
-
Queen Creek, Arizona, Vereinigte Staaten, 85140
- Rekrutierung
- East Valley Urology Center of Arizona
-
Kontakt:
- Use Central Contact
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72211
- Rekrutierung
- Arkansas Urology
-
Kontakt:
- Use Central Contact
-
-
California
-
Bakersfield, California, Vereinigte Staaten, 93301
- Rekrutierung
- Michael Oefelein Clinical Trials
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30319
- Rekrutierung
- Urology of Greater Atlanta - Sandy Springs
-
Kontakt:
- Use Central Contact
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Renown Regional Medical Center
-
Kontakt:
- Use Central Contact
-
-
South Carolina
-
Myrtle Beach, South Carolina, Vereinigte Staaten, 29572
- Rekrutierung
- START - Carolinas
-
Kontakt:
- Use Central Contact
-
-
Texas
-
Arlington, Texas, Vereinigte Staaten, 76017
- Rekrutierung
- Urology Partners of North Texas
-
Kontakt:
- Use Central Contact
-
Austin, Texas, Vereinigte Staaten, 78745
- Rekrutierung
- Urology Austin, LLC
-
Kontakt:
- Use Central Contact
-
Houston, Texas, Vereinigte Staaten, 77027
- Rekrutierung
- Houston Metro Urology
-
Kontakt:
- Use Central Contact
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female participants 18 years of age or older at the time of signing informed consent
- Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
- Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
- Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis, or participants who received ≤2 doses of BCG within the 24 months prior to the most recent CIS diagnosis
Exclusion Criteria:
- Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory
- Central confirmed variant histology
- Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
- Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)
- Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history
For more information on eligibility criteria, please contact the Sponsor.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: TARA-002 (Arm A)
|
Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. |
|
Aktiver Komparator: Untersuchungsleiterwahl der intravesikalen Chemotherapie
|
Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of high-grade complete response
Zeitfenster: Month 6
|
Incidence of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) |
Month 6
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Duration of high-grade complete response
Zeitfenster: Up to Month 60
|
Duration of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Treatment emergent adverse events
Zeitfenster: Up to Month 60
|
Incidence and severity of treatment emergent adverse events (TEAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Treatment emergent serious adverse events
Zeitfenster: Up to Month 60
|
Incidence and severity of treatment emergent serious adverse events (TESAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
High-grade complete response rate
Zeitfenster: At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
|
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) |
At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
|
|
High-grade complete response rate (CIS only)
Zeitfenster: Month 6
|
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) in sub-group of participants with CIS only |
Month 6
|
|
Event-free survival
Zeitfenster: Up to Month 60
|
Event-free survival (EFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Recurrence-free survival
Zeitfenster: Up to Month 60
|
Recurrence-free survival (RFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Progression-free survival
Zeitfenster: Up to Month 60
|
Progression-free survival (PFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Disease-specific progression-free survival
Zeitfenster: Up ro Month 60
|
Disease-specific progression-free survival (DSPFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up ro Month 60
|
|
Overall survival
Zeitfenster: Up to Month 60
|
Overall survival (OS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Disease-specific survival
Zeitfenster: Up to Month 60
|
Disease-specific survival (DSS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to cystectomy
Zeitfenster: Up to Month 60
|
Time to cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to recurrence delayed cystectomy
Zeitfenster: Up to Month 60
|
Time to recurrence delayed cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to progression
Zeitfenster: Up to Month 60
|
Time to progression of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to disease worsening
Zeitfenster: Up to Month 60
|
Time to disease worsening of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Männliche Urogenitalerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Urologische Neubildungen
- Karzinom
- Erkrankungen der Harnblase
- Nicht-muskelinvasive Blasenneoplasien
- Neubildungen
- Karzinom in situ
- Neoplasien der Harnblase
Andere Studien-ID-Nummern
- TARA-002-301
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .